TLDR Alopecia areata patients show unique protein activity patterns, suggesting imbalanced signaling pathways.
The study applied a multiplex matrix system to analyze protein complexes in the T cell receptor (TCR) signalosome, focusing on samples from Jurkat cells and 7 alopecia areata patients compared to 5 controls. It identified distinct PiSCES biosignatures in alopecia areata patients, characterized by enhanced basal TCR signaling network activity and a potential imbalance between GADS and GRB2 activity. This imbalance might influence pathways related to cytoskeletal remodeling and integrin signaling. The study demonstrated that PiSCES analysis could effectively distinguish between disease and control conditions, providing insights into the underlying signaling pathways involved in alopecia areata. Despite limitations in detecting all protein interactions, the approach offered valuable insights into protein network activities and potential disease pathways.
421 citations,
April 2012 in “The New England Journal of Medicine” Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.
717 citations,
June 2010 in “Nature” Alopecia areata involves both innate and adaptive immunity, with specific genes linked to the disease.
[object Object]
4 citations,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
[object Object] 
60 citations,
September 2015 in “Expert Review of Clinical Immunology” Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.
67 citations,
January 2020 in “Cellular & Molecular Immunology/Cellular & molecular immunology” Tissue-resident memory T cells can protect against infections and cancer but may also contribute to autoimmune diseases.
15 citations,
April 2003 in “Journal of dermatology” Alopecia areata causes hair loss due to an immune attack on hair follicles, influenced by genetics and environment.
23 citations,
January 2016 in “Frontiers in immunology” Using low-dose IL-2 to increase regulatory T cells might be a safe way to treat type 1 diabetes without severe side effects.
